JP6047295B2 - Mucosal composition - Google Patents
Mucosal composition Download PDFInfo
- Publication number
- JP6047295B2 JP6047295B2 JP2012081822A JP2012081822A JP6047295B2 JP 6047295 B2 JP6047295 B2 JP 6047295B2 JP 2012081822 A JP2012081822 A JP 2012081822A JP 2012081822 A JP2012081822 A JP 2012081822A JP 6047295 B2 JP6047295 B2 JP 6047295B2
- Authority
- JP
- Japan
- Prior art keywords
- component
- weight
- sulfate
- composition
- sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 61
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 64
- 210000004877 mucosa Anatomy 0.000 claims description 34
- 239000002280 amphoteric surfactant Substances 0.000 claims description 33
- 229960003237 betaine Drugs 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 32
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 30
- -1 alkyl sulfate ester Chemical class 0.000 claims description 24
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 21
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 20
- 229960002449 glycine Drugs 0.000 claims description 15
- 235000013905 glycine and its sodium salt Nutrition 0.000 claims description 15
- PSBDWGZCVUAZQS-UHFFFAOYSA-N (dimethylsulfonio)acetate Chemical compound C[S+](C)CC([O-])=O PSBDWGZCVUAZQS-UHFFFAOYSA-N 0.000 claims description 13
- 229940117986 sulfobetaine Drugs 0.000 claims description 13
- 210000000214 mouth Anatomy 0.000 claims description 9
- 210000003928 nasal cavity Anatomy 0.000 claims description 9
- 210000003800 pharynx Anatomy 0.000 claims description 7
- 210000001215 vagina Anatomy 0.000 claims description 6
- 229950005425 sodium myristyl sulfate Drugs 0.000 claims description 5
- 210000003932 urinary bladder Anatomy 0.000 claims description 5
- 210000000664 rectum Anatomy 0.000 claims description 4
- 229940067741 sodium octyl sulfate Drugs 0.000 claims description 4
- XZTJQQLJJCXOLP-UHFFFAOYSA-M sodium;decyl sulfate Chemical compound [Na+].CCCCCCCCCCOS([O-])(=O)=O XZTJQQLJJCXOLP-UHFFFAOYSA-M 0.000 claims description 4
- GGHPAKFFUZUEKL-UHFFFAOYSA-M sodium;hexadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCOS([O-])(=O)=O GGHPAKFFUZUEKL-UHFFFAOYSA-M 0.000 claims description 4
- NWZBFJYXRGSRGD-UHFFFAOYSA-M sodium;octadecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCOS([O-])(=O)=O NWZBFJYXRGSRGD-UHFFFAOYSA-M 0.000 claims description 4
- WFRKJMRGXGWHBM-UHFFFAOYSA-M sodium;octyl sulfate Chemical compound [Na+].CCCCCCCCOS([O-])(=O)=O WFRKJMRGXGWHBM-UHFFFAOYSA-M 0.000 claims description 4
- 108010001682 Dextranase Proteins 0.000 claims 2
- UPUIQOIQVMNQAP-UHFFFAOYSA-M sodium;tetradecyl sulfate Chemical compound [Na+].CCCCCCCCCCCCCCOS([O-])(=O)=O UPUIQOIQVMNQAP-UHFFFAOYSA-M 0.000 claims 2
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 claims 1
- 230000007794 irritation Effects 0.000 description 28
- 210000004400 mucous membrane Anatomy 0.000 description 27
- 230000000694 effects Effects 0.000 description 21
- 230000003833 cell viability Effects 0.000 description 16
- 238000004140 cleaning Methods 0.000 description 14
- 238000000034 method Methods 0.000 description 14
- 229940043264 dodecyl sulfate Drugs 0.000 description 11
- 150000008051 alkyl sulfates Chemical class 0.000 description 10
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 10
- XPALGXXLALUMLE-UHFFFAOYSA-N 2-(dimethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(N(C)C)C(O)=O XPALGXXLALUMLE-UHFFFAOYSA-N 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 8
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 8
- DDGPBVIAYDDWDH-UHFFFAOYSA-N 3-[dodecyl(dimethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC[N+](C)(C)CC(O)CS([O-])(=O)=O DDGPBVIAYDDWDH-UHFFFAOYSA-N 0.000 description 7
- 238000002835 absorbance Methods 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 230000000052 comparative effect Effects 0.000 description 6
- 210000002615 epidermis Anatomy 0.000 description 6
- 210000002200 mouth mucosa Anatomy 0.000 description 6
- 231100000017 mucous membrane irritation Toxicity 0.000 description 6
- BKUWWVKLLKXDJK-UHFFFAOYSA-N 2-(dimethylamino)icosanoic acid Chemical compound CCCCCCCCCCCCCCCCCCC(N(C)C)C(O)=O BKUWWVKLLKXDJK-UHFFFAOYSA-N 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000005406 washing Methods 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 239000005639 Lauric acid Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 3
- 125000001421 myristyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 150000003839 salts Chemical group 0.000 description 3
- URLJMZWTXZTZRR-UHFFFAOYSA-N sodium myristyl sulfate Chemical compound CCCCCCCCCCCCCCOS(O)(=O)=O URLJMZWTXZTZRR-UHFFFAOYSA-N 0.000 description 3
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 241000700199 Cavia porcellus Species 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000003945 anionic surfactant Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 239000012459 cleaning agent Substances 0.000 description 2
- 235000019864 coconut oil Nutrition 0.000 description 2
- 239000003240 coconut oil Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000011086 high cleaning Methods 0.000 description 2
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XQXCSIXQJDKACR-UHFFFAOYSA-N 2-(dimethylamino)octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCC(N(C)C)C(O)=O XQXCSIXQJDKACR-UHFFFAOYSA-N 0.000 description 1
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- IXOCGRPBILEGOX-UHFFFAOYSA-N 3-[3-(dodecanoylamino)propyl-dimethylazaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC(O)CS([O-])(=O)=O IXOCGRPBILEGOX-UHFFFAOYSA-N 0.000 description 1
- 125000000972 4,5-dimethylthiazol-2-yl group Chemical group [H]C([H])([H])C1=C(N=C(*)S1)C([H])([H])[H] 0.000 description 1
- GPDIKHKTFOIWTN-UHFFFAOYSA-N 5,5-diphenyltetrazol-1-ium bromide Chemical compound Br.C1=CC=C(C=C1)C1(N=NN=N1)C1=CC=CC=C1 GPDIKHKTFOIWTN-UHFFFAOYSA-N 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-M Aminoacetate Chemical compound NCC([O-])=O DHMQDGOQFOQNFH-UHFFFAOYSA-M 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000870659 Crassula perfoliata var. minor Species 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- 231100000960 LabCyte EPI-MODEL 24 Toxicity 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000001705 Mouth breathing Diseases 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- QBKPMSKQOVQLMB-UHFFFAOYSA-N NCC(O)=O.CCCCCCCCCCCC(O)=O Chemical compound NCC(O)=O.CCCCCCCCCCCC(O)=O QBKPMSKQOVQLMB-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- SLINHMUFWFWBMU-UHFFFAOYSA-N Triisopropanolamine Chemical compound CC(O)CN(CC(C)O)CC(C)O SLINHMUFWFWBMU-UHFFFAOYSA-N 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000012911 assay medium Substances 0.000 description 1
- 230000001680 brushing effect Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000002826 coolant Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- LVTYICIALWPMFW-UHFFFAOYSA-N diisopropanolamine Chemical compound CC(O)CNCC(C)O LVTYICIALWPMFW-UHFFFAOYSA-N 0.000 description 1
- 229940043276 diisopropanolamine Drugs 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- ILRSCQWREDREME-UHFFFAOYSA-N dodecanamide Chemical compound CCCCCCCCCCCC(N)=O ILRSCQWREDREME-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 206010013781 dry mouth Diseases 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 235000011167 hydrochloric acid Nutrition 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000009781 safety test method Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- HHBXRAJZJYYTFZ-UHFFFAOYSA-M sodium 2-(dimethylamino)icosanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCCC(N(C)C)C([O-])=O HHBXRAJZJYYTFZ-UHFFFAOYSA-M 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
Description
本発明は、優れた洗浄効果を有しながらも粘膜に対する刺激が抑制された粘膜適用組成物に関する。 The present invention relates to a composition for applying to mucosa, which has an excellent cleaning effect and suppresses irritation to mucous membranes.
咽頭、鼻腔、膣等の粘膜においては、異物が付着することにより不快感や炎症が生じることが知られている。このような粘膜における症状を予防及び改善するためには、粘膜用の洗浄液等によって粘膜の異物を除去することが有効であるとされている。洗浄の際、界面活性剤等の洗浄剤を使用することによって、優れた洗浄効果を発揮させることができ、当該界面活性剤としては、アニオン性界面活性剤が一般的である。なかでも、ラウリル硫酸塩等に代表されるアルキル硫酸エステル型界面活性剤は、洗浄作用に優れていることが知られている。しかしながら、アルキル硫酸エステル型界面活性剤は、通常皮膚や毛髪に適用されるものであり、咽頭、鼻腔、膣、口腔等の粘膜に対しては強い刺激があるため、低濃度でなければ、粘膜に適用した場合に赤く腫れたり(紅斑)、粘膜がはがれたりすることがある。従って、アルキル硫酸エステル型界面活性剤は、洗浄効果が優れているにも関わらず、粘膜への使用は敬遠されている。 It is known that in the mucous membranes such as the pharynx, nasal cavity, and vagina, discomfort and inflammation are caused by adhesion of foreign substances. In order to prevent and ameliorate such symptoms in the mucous membrane, it is considered effective to remove the mucosal foreign matter with a mucous membrane washing solution or the like. By using a cleaning agent such as a surfactant at the time of cleaning, an excellent cleaning effect can be exhibited. As the surfactant, an anionic surfactant is generally used. Among these, alkyl sulfate type surfactants represented by lauryl sulfate and the like are known to have an excellent cleaning action. However, alkyl sulfate type surfactants are usually applied to the skin and hair, and have strong irritation to mucous membranes such as the pharynx, nasal cavity, vagina and oral cavity. When applied to the skin, it may swell red (erythema) or the mucous membrane may peel off. Therefore, the alkyl sulfate ester type surfactant is not used for mucous membranes despite its excellent cleaning effect.
また、口腔粘膜については、近年、口呼吸の増加、老化、ストレス、薬の副作用等を原因とする唾液の分泌量の低下により、口腔内、特に口腔粘膜が乾燥している人が増加している。口腔粘膜が乾燥すると、口腔粘膜の刺激感受性が高まるため、アルキル硫酸エステル型界面活性剤を含む口腔用洗浄剤等を使用すると、強い刺激を感じ、不快感を生じる。そのため、口腔用洗浄剤に含有されるアルキル硫酸エステル型界面活性剤の量には制約があった。 In addition, with regard to oral mucosa, in recent years, there has been an increase in the number of people who have dry mouth, especially oral mucosa, due to the decrease in saliva secretion due to increased mouth breathing, aging, stress, drug side effects, etc. Yes. When the oral mucosa is dried, the irritation sensitivity of the oral mucosa is increased. Therefore, when an oral detergent containing an alkyl sulfate ester type surfactant is used, a strong irritation is felt and discomfort is generated. For this reason, there is a restriction on the amount of the alkyl sulfate type surfactant contained in the oral cleaning agent.
このような背景から、アルキル硫酸エステル型界面活性剤である、ラウリル硫酸塩に起因する刺激を低減するための方法が検討され、ラウリル硫酸塩と脂肪酸アミドプロピルベタインを所定量含有する、低刺激性の歯磨組成物(例えば特許文献1を参照)等が提案されている。しかしながら、特許文献1に記載される組成物には、ラウリル硫酸塩が含有されているものの、その含有量は0.2〜0.7重量%と少量であり、ラウリル硫酸塩による洗浄効果はそれほど期待できるものではなく、そもそもラウリル硫酸塩の含有量が少量であるために刺激が低減されているものと考えられる。即ち、ラウリル硫酸塩を高濃度で含有することにより、優れた洗浄効果を奏しながらも、粘膜に対する刺激が低減された組成物は未だ得られていなかった。 Against this background, a method for reducing irritation caused by lauryl sulfate, which is an alkyl sulfate ester type surfactant, has been studied, and contains a predetermined amount of lauryl sulfate and fatty acid amidopropyl betaine. A dentifrice composition (see, for example, Patent Document 1) has been proposed. However, although the composition described in Patent Document 1 contains lauryl sulfate, its content is as small as 0.2 to 0.7% by weight, and the cleaning effect by lauryl sulfate is not so much. In the first place, it is considered that the irritation is reduced because the content of lauryl sulfate is small. That is, by containing lauryl sulfate at a high concentration, a composition in which irritation to the mucous membrane was reduced while exhibiting an excellent cleaning effect has not yet been obtained.
本発明は、優れた洗浄効果を有し、且つ粘膜に対する刺激が抑制された粘膜適用組成物を提供することを主な目的とする。 The main object of the present invention is to provide a composition for applying to mucosa which has an excellent cleaning effect and suppresses irritation to mucous membranes.
本発明者らは上記課題を解決すべく鋭意検討を行った結果、アルキル硫酸エステル型界面活性剤と、アミノ酢酸ベタイン型両性界面活性剤及び/又はスルホベタイン型両性界面活性剤を所定の含有比率で含有する組成物は、粘膜に適用した際に十分な洗浄効果を奏しながらも、アルキル硫酸エステル型界面活性剤に起因する刺激が抑制され、使用感に優れたものであることを見出した。本発明は、このような知見に基づいて更に研究を重ねた結果完成されたものである。即ち、本発明は下記態様の粘膜適用組成物を提供する。
項1.(A)アルキル硫酸エステル型界面活性剤と、(B)アミノ酢酸ベタイン型両性界面活性剤及びスルホベタイン型両性界面活性剤からなる群より選択される少なくとも1種の界面活性剤とを含み、
用時の(A)成分の含有量が1.5重量%以上、
(B)成分の含有量が(A)成分1重量部に対して0.2〜2.8重量部である粘膜適用組成物。
項2.用時の(A)成分の含有量が1.5〜5重量%である、項1に記載の粘膜適用組成物。
項3.(A)成分がオクチル硫酸ナトリウム、デシル硫酸ナトリウム、ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム、パルミチル硫酸ナトリウム及びステアリル硫酸ナトリウムからなる群より選択される、項1又は2に記載の粘膜適用組成物。
項4.(B)成分がアミノ酢酸ベタイン型両性界面活性剤である、項1〜3のいずれかに記載の粘膜適用組成物。
項5.(B)成分の含有量が(A)成分1重量部に対して0.4〜2.5重量部である、項4に記載の粘膜適用組成物。
項6.(B)成分がスルホベタイン型両性界面活性剤である、項1〜3のいずれかに記載の粘膜適用組成物。
項7.(B)成分の含有量が(A)成分1重量部に対して0.3〜2.5重量部である、項6に記載の粘膜適用組成物。
項8.粘膜が鼻腔、咽頭、口腔、耳、膣、膀胱及び直腸からなる群より選択される少なくとも1種の粘膜である、項1〜7のいずれかに記載の粘膜適用組成物。
As a result of intensive studies to solve the above problems, the present inventors have found that a predetermined content ratio of alkyl sulfate ester type surfactant, aminoacetic acid betaine type amphoteric surfactant and / or sulfobetaine type amphoteric surfactant It has been found that the composition contained in (1) has a satisfactory feeling of use due to the suppression of irritation caused by the alkylsulfuric acid ester type surfactant while exhibiting a sufficient cleaning effect when applied to the mucous membrane. The present invention has been completed as a result of further research based on such knowledge. That is, this invention provides the composition for mucosa of the following aspect.
Item 1. (A) an alkyl sulfate ester type surfactant and (B) at least one surfactant selected from the group consisting of an aminoacetic acid betaine type amphoteric surfactant and a sulfobetaine type amphoteric surfactant,
The content of the component (A) at the time of use is 1.5% by weight or more,
(B) The composition applied to mucosa in which the content of the component is 0.2 to 2.8 parts by weight with respect to 1 part by weight of the component (A).
Item 2. Item 2. The composition for applying to mucosa according to Item 1, wherein the content of the component (A) at the time of use is 1.5 to 5% by weight.
Item 3. Item 3. The mucosa-applied composition according to Item 1 or 2, wherein the component (A) is selected from the group consisting of sodium octyl sulfate, sodium decyl sulfate, sodium lauryl sulfate, sodium myristyl sulfate, sodium palmityl sulfate, and sodium stearyl sulfate.
Item 4. Item 4. The composition for applying to mucosa according to any one of Items 1 to 3, wherein the component (B) is an aminoacetic acid betaine amphoteric surfactant.
Item 5. Item 5. The composition for applying to mucosa according to Item 4, wherein the content of the component (B) is 0.4 to 2.5 parts by weight with respect to 1 part by weight of the component (A).
Item 6. Item 4. The composition for applying to mucosa according to any one of Items 1 to 3, wherein the component (B) is a sulfobetaine type amphoteric surfactant.
Item 7. Item 7. The composition for applying to mucosa according to Item 6, wherein the content of the component (B) is 0.3 to 2.5 parts by weight with respect to 1 part by weight of the component (A).
Item 8. Item 8. The composition for applying to mucosa according to any one of Items 1 to 7, wherein the mucous membrane is at least one mucosa selected from the group consisting of nasal cavity, pharynx, oral cavity, ear, vagina, bladder and rectum.
本発明によれば、高濃度でアルキル硫酸エステル型界面活性剤を含有することにより、優れた洗浄効果を達成することができる。しかも、高濃度のアルキル硫酸エステル型界面活性剤は粘膜に対する刺激が強いため、従来は粘膜への適用が困難であったところ、本発明の粘膜適用組成物はこのような粘膜への刺激が低減されたものである。従って、本発明の粘膜適用組成物によれば、高い洗浄効果と優れた使用感を同時に実現することが可能である。 According to the present invention, an excellent cleaning effect can be achieved by containing an alkyl sulfate ester type surfactant at a high concentration. In addition, since a high concentration of alkyl sulfate type surfactant has strong irritation to mucous membranes, it has been difficult to apply to mucous membranes conventionally. However, the composition applied to mucosa of the present invention reduces such irritation to mucous membranes. It has been done. Therefore, according to the composition for applying to mucosa of the present invention, it is possible to simultaneously realize a high cleaning effect and an excellent usability.
本発明の粘膜適用組成物は、(A)アルキル硫酸エステル型界面活性剤と、(B)アミノ酢酸ベタイン型両性界面活性剤及びスルホベタイン型両性界面活性剤からなる群より選択される少なくとも1種の界面活性剤を含み、用時の(A)成分の含有量が1.5重量%以上、(B)成分の含有量が(A)成分1重量部に対して0.2〜2.8重量部であることを特徴とする。以下、本発明の粘膜適用組成物を「本発明の組成物」と略記することがある。 The composition for applying to mucosa of the present invention is at least one selected from the group consisting of (A) an alkyl sulfate type surfactant and (B) an aminoacetic acid betaine type amphoteric surfactant and a sulfobetaine type amphoteric surfactant. The amount of the component (A) at the time of use is 1.5% by weight or more, and the content of the component (B) is 0.2 to 2.8 with respect to 1 part by weight of the component (A). It is a weight part. Hereinafter, the composition applied to mucosa of the present invention may be abbreviated as “the composition of the present invention”.
(A)成分
(A)成分として使用されるアルキル硫酸エステル型界面活性剤(以下、「(A)成分」と略記することがある)としては、特に制限されず、アニオン性界面活性剤として一般に使用されているものを広く用いることができる。
(A) Component The alkyl sulfate ester type surfactant used as the component (A) (hereinafter sometimes abbreviated as “(A) component”) is not particularly limited, and is generally used as an anionic surfactant. Widely used ones can be used.
アルキル硫酸エステル型界面活性剤を構成するアルキル基の炭素数については、特に制限されないが、例えば8〜20、好ましくは10〜18、更に好ましくは10〜16が挙げられる。また、アルキル硫酸エステル型界面活性剤を構成するアルキル基は、直鎖状、分岐状のいずれであってもよいが、好ましくは直鎖状が挙げられる。また、アルキル硫酸エステル型界面活性剤としては、フリー体又は塩の形態のいずれを使用してもよい。アルキル硫酸エステル型界面活性剤の塩としては、ナトリウム、カリウム、マグネシウム等のアルカリ金属塩、アルカリ土類金属塩、又はアンモニウム塩等が挙げられる。 Although it does not restrict | limit especially about carbon number of the alkyl group which comprises an alkyl sulfate ester type surfactant, For example, 8-20, Preferably it is 10-18, More preferably, 10-16 is mentioned. Moreover, the alkyl group constituting the alkyl sulfate ester type surfactant may be either linear or branched, but preferably is linear. In addition, as the alkyl sulfate ester type surfactant, either a free form or a salt form may be used. Examples of the salt of the alkyl sulfate ester type surfactant include alkali metal salts such as sodium, potassium and magnesium, alkaline earth metal salts, and ammonium salts.
アルキル硫酸エステル型界面活性剤として、具体的には、オクチル硫酸ナトリウム、デシル硫酸ナトリウム、ラウリル硫酸ナトリウム、ミリスチル硫酸ナトリウム、パルミチル硫酸ナトリウム、ステアリル硫酸ナトリウム等が挙げられる。本発明の組成物においては、アルキル硫酸エステル型界面活性剤を1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。これらのアルキル硫酸エステル型界面活性剤の中でも、洗浄効果が高いことから、ラウリル硫酸塩及びミリスチル硫酸塩が挙げられ、好ましくはラウリル硫酸塩、より好ましくはラウリル硫酸アルカリ金属塩、更に好ましくはラウリル硫酸ナトリウムが挙げられる。ラウリル硫酸ナトリウムについては、例えば、第一工業製薬株式会社、花王株式会社等から商業的に入手可能である。 Specific examples of the alkyl sulfate type surfactant include sodium octyl sulfate, sodium decyl sulfate, sodium lauryl sulfate, sodium myristyl sulfate, sodium palmityl sulfate, and sodium stearyl sulfate. In the composition of the present invention, the alkyl sulfate ester type surfactant may be used alone or in combination of two or more. Among these alkyl sulfate ester type surfactants, lauryl sulfate and myristyl sulfate are preferred because of their high cleaning effect, preferably lauryl sulfate, more preferably alkali metal lauryl sulfate, and more preferably lauryl sulfate. Sodium is mentioned. Sodium lauryl sulfate is commercially available from, for example, Daiichi Kogyo Seiyaku Co., Ltd. and Kao Corporation.
本発明の組成物において、用時における(A)成分の含有量は、通常1.5重量%以上、好ましくは1.5〜5重量%、より好ましくは2.5〜5重量%更に好ましくは3〜5重量%、特に好ましくは3〜4重量%が挙げられる。このような範囲で(A)成分を含有することにより、アルキル硫酸エステル型界面活性剤による優れた洗浄効果が得られ、更に、後述するアミノ酢酸ベタイン型両性界面活性剤又はスルホベタイン型両性界面活性剤を含有させることによる刺激低減効果が高いため好ましい。本発明の組成物は、このように(A)成分を高濃度で含有しながらも粘膜への刺激が抑制され、使用感に優れたものである。なお、本明細書において「用時における含有量」とは、本発明の組成物が粘膜に適用される際に含まれる各成分の含有量を指す。 In the composition of the present invention, the content of the component (A) at the time of use is usually 1.5% by weight or more, preferably 1.5 to 5% by weight, more preferably 2.5 to 5% by weight, still more preferably. 3 to 5 weight%, Especially preferably 3 to 4 weight% is mentioned. By containing the component (A) in such a range, an excellent washing effect by the alkyl sulfate ester type surfactant is obtained, and further, an aminoacetic acid betaine type amphoteric surfactant or a sulfobetaine type amphoteric surfactant described later. It is preferable because the effect of reducing irritation due to the inclusion of the agent is high. As described above, the composition of the present invention has excellent usability because the irritation to the mucous membrane is suppressed while containing the component (A) at a high concentration. In the present specification, the “content at the time of use” refers to the content of each component included when the composition of the present invention is applied to the mucous membrane.
(B)成分
本発明において両性界面活性剤として、下記一般式に示されるアミノ酢酸ベタイン型両性界面活性剤及び/又はスルホベタイン型両性界面活性剤が使用される。以下、これらの界面活性剤を「(B)成分」と略記することがある。
(B) Component In the present invention, an aminoacetic acid betaine type amphoteric surfactant and / or a sulfobetaine type amphoteric surfactant represented by the following general formula is used as the amphoteric surfactant. Hereinafter, these surfactants may be abbreviated as “component (B)”.
本発明において(B)成分として使用されるアミノ酢酸ベタイン型両性界面活性剤は、下記一般式(1)で示される。
式(1)中、R1は炭素数8〜22、好ましくは炭素数10〜18の直鎖状又は分岐鎖状のアルキル基若しくはアルケニル基を表す。R1としては、例えば、デシル基、ラウリル基、ミルスチル基、パルミチル基、ステアリル基、オレイル基等が挙げられ、好ましくはラウリル基、パルミチル基、ステアリル基等が挙げられる。また、式(1)中、aは1又は0を表す。 In the formula (1), R 1 represents a linear or branched alkyl group or alkenyl group having 8 to 22 carbon atoms, preferably 10 to 18 carbon atoms. Examples of R 1 include a decyl group, a lauryl group, a myristyl group, a palmityl group, a stearyl group, and an oleyl group, and preferably a lauryl group, a palmityl group, a stearyl group, and the like. In the formula (1), a represents 1 or 0.
また、式(1)中、R2及びR3は同一又は異なって炭素数1〜4の直鎖状又は分岐鎖状のアルキル基又はヒドロキシアルキル基を表し、例えば、メチル基、エチル基、プロピル基、ヒドロキシメチル基、ヒドロキシエチル基等が挙げられ、好ましくはメチル基又はヒドロキシエチル基が挙げられる。 In the formula (1), R 2 and R 3 are the same or different and represent a linear or branched alkyl group or hydroxyalkyl group having 1 to 4 carbon atoms, such as methyl group, ethyl group, propyl Group, hydroxymethyl group, hydroxyethyl group and the like, preferably methyl group or hydroxyethyl group.
アミノ酢酸ベタイン型両性界面活性剤の具体例としては、ヤシ油アルキルジメチルアミノ酢酸ベタイン、ラウリルジメチルアミノ酢酸ベタイン、ラウリン酸アミノ酢酸ベタイン、パルミチルジメチルアミノ酢酸ベタイン、ステアリルジメチルアミノ酢酸ベタイン、ステアリルジヒドロキシエチルベタイン等が例示され、好ましくはラウリルジメチルアミノ酢酸ベタイン、ステアリルジメチルアミノ酢酸ベタインが挙げられる。これらアミノ酢酸ベタイン型両性界面活性剤を1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。アミノ酢酸ベタイン型両性界面活性剤については、例えば、新日本理化株式会社、花王株式会社、三洋化成工業株式会社等から商業的に入手可能である。 Specific examples of aminoacetic acid betaine type amphoteric surfactants include coconut oil alkyldimethylaminoacetic acid betaine, lauryldimethylaminoacetic acid betaine, lauric acid aminoacetic acid betaine, palmityldimethylaminoacetic acid betaine, stearyldimethylaminoacetic acid betaine, stearyl dihydroxyethyl Betaine and the like are exemplified, and preferred are lauryldimethylaminoacetic acid betaine and stearyldimethylaminoacetic acid betaine. These aminoacetic acid betaine-type amphoteric surfactants may be used alone or in combination of two or more. Aminoacetic acid betaine amphoteric surfactants are commercially available from, for example, Shin Nippon Rika Co., Ltd., Kao Corporation, Sanyo Chemical Industries, Ltd., and the like.
本発明において、(B)成分として使用されるスルホベタイン型両性界面活性剤は、下記一般式(2)で示される。
式(2)中、R4は炭素数9〜21、好ましくは11〜16の直鎖状又は分岐鎖状のアルキル基又はアルケニル基を表し、例えば、ラウリル基、ミルスチル基、パルミチル基、ステアリル基、オレイル基等が挙げられ、好ましくはラウリル基、ミルスチル基等が挙げられる。 In the formula (2), R 4 represents a linear or branched alkyl group or alkenyl group having 9 to 21 carbon atoms, preferably 11 to 16, for example, lauryl group, myristyl group, palmityl group, stearyl group. Oleyl group and the like, preferably lauryl group, myristyl group and the like.
また、式(2)中、R5及びR6は同一又は異なって、炭素数1〜4の直鎖状若しくは分岐鎖状のアルキル基若しくはヒドロキシアルキル基、又は−(CH2CH2O)pH(pは1〜3の整数を表す)を表し、Qは−CH2CH(OH)CH2SO3、又は−(CH2)qSO3(qは1〜3の整数を表す)を表し、cは1〜4の整数を示し、dは0又は1を表す。Qとして好ましくは−CH2CH(OH)CH2SO3が挙げられる。R5及びR6で表されるアルキル基又はヒドロキシアルキル基としては、例えば、メチル基、エチル基、プロピル基、ヒドロキシメチル基、ヒドロキシエチル基等が挙げられ、好ましくはメチル基が挙げられる。 In the formula (2), R 5 and R 6 are the same or different and are each a linear or branched alkyl group or hydroxyalkyl group having 1 to 4 carbon atoms, or — (CH 2 CH 2 O) p. H (p represents an integer of 1 to 3), Q represents —CH 2 CH (OH) CH 2 SO 3 , or — (CH 2 ) q SO 3 (q represents an integer of 1 to 3). C represents an integer of 1 to 4, and d represents 0 or 1. Q is preferably —CH 2 CH (OH) CH 2 SO 3 . Examples of the alkyl group or hydroxyalkyl group represented by R 5 and R 6 include a methyl group, an ethyl group, a propyl group, a hydroxymethyl group, a hydroxyethyl group, and preferably a methyl group.
前記式(2)により表されるスルホベタイン型両性界面活性剤としては、例えば、アルキルスルホベタイン、アルキルヒドロキシスルホベタイン、アルキルアミドスルホベタイン等が挙げられる。 Examples of the sulfobetaine-type amphoteric surfactant represented by the formula (2) include alkyl sulfobetaines, alkylhydroxysulfobetaines, and alkylamide sulfobetaines.
スルホベタイン型両性界面活性剤の具体例としては、ラウリルヒドロキシスルホベタイン、ラウリン酸アミドプロピルヒドロキシスルホベタイン、ミリスチン酸アミドプロピルヒドロキシスルホベタイン、ヤシ油脂肪酸アミドプロピルヒドロキシスルホベタイン等が例示され、好ましくはラウリルヒドロキシスルホベタイン、ラウリン酸アミドプロピルヒドロキシスルホベタインが挙げられる。これらのスルホベタイン型両性界面活性剤を1種単独で使用してもよく、また2種以上を組み合わせて使用してもよい。スルホベタイン型両性界面活性剤については、例えば、川研ファインケミカル株式会社、松本油脂製薬株式会社、花王株式会社、三洋化成工業株式会社等から商業的に入手可能である。 Specific examples of the sulfobetaine type amphoteric surfactants include lauryl hydroxysulfobetaine, lauric acid amidopropyl hydroxysulfobetaine, myristic acid amidopropyl hydroxysulfobetaine, coconut oil fatty acid amidopropyl hydroxysulfobetaine, and preferably lauryl. Examples thereof include hydroxysulfobetaine and lauric acid amidopropyl hydroxysulfobetaine. These sulfobetaine type amphoteric surfactants may be used alone or in combination of two or more. The sulfobetaine-type amphoteric surfactant is commercially available from, for example, Kawaken Fine Chemical Co., Ltd., Matsumoto Yushi Seiyaku Co., Ltd., Kao Corporation, Sanyo Chemical Industries, Ltd.
本発明の組成物において、粘膜への刺激が一層顕著に低減されるという観点から、(B)成分として好ましくは、ラウリルジメチルアミノ酢酸ベタイン、ステアリルジメチルアミノ酢酸ベタイン、ラウリルヒドロキシスルホベタイン及びラウリン酸アミドプロピルヒドロキシスルホベタインからなる群より選択される少なくともいずれか1種が挙げられる。 In the composition of the present invention, from the viewpoint that irritation to the mucous membrane is more remarkably reduced, the component (B) is preferably lauryldimethylaminoacetic acid betaine, stearyldimethylaminoacetic acid betaine, laurylhydroxysulfobetaine and lauric acid amide. And at least one selected from the group consisting of propylhydroxysulfobetaine.
本発明の組成物中の用時の(B)成分の含有量は、前記(A)成分1重量部に対して0.2〜2.8重量部に設定され、このような含有量で(B)成分を含有することにより、(A)成分による優れた洗浄効果を発揮しながら、粘膜への刺激を低減することができる。粘膜への刺激をより一層低減するという観点から、用時の(B)成分の含有量は、好ましくは前記(A)成分1重量部に対して0.3〜2.5重量部、より好ましくは0.4〜2.5重量部、更に好ましくは0.5〜2.5重量部が挙げられる。ここで(B)成分の含有量は、(B)成分として2以上の化合物を使用する場合にはそれらの総量とする。 The content of the component (B) at the time of use in the composition of the present invention is set to 0.2 to 2.8 parts by weight with respect to 1 part by weight of the component (A). By containing the component B), it is possible to reduce irritation to the mucous membrane while exhibiting the excellent cleaning effect of the component (A). From the viewpoint of further reducing irritation to the mucous membrane, the content of the component (B) at the time of use is preferably 0.3 to 2.5 parts by weight, more preferably 1 part by weight of the component (A). Is 0.4 to 2.5 parts by weight, more preferably 0.5 to 2.5 parts by weight. Here, the content of the component (B) is the total amount when two or more compounds are used as the component (B).
また、特に、(B)成分がアミノ酢酸ベタイン型両性界面活性剤の場合、(B)成分の含有量が(A)成分1重量部に対して0.2〜2.8重量部、好ましくは0.4〜2.5重量部、更に好ましくは0.5〜2.5重量部が挙げられる。 In particular, when the component (B) is an aminoacetic acid betaine type amphoteric surfactant, the content of the component (B) is 0.2 to 2.8 parts by weight, preferably 1 part by weight of the component (A). 0.4-2.5 weight part is mentioned, More preferably, 0.5-2.5 weight part is mentioned.
また、特に、(B)成分がスルホベタイン型両性界面活性剤の場合、(B)成分の含有量が(A)成分1重量部に対して0.2〜2.8重量部、好ましくは0.3〜2.5重量部、より好ましくは0.4〜2.5重量部、更に好ましくは0.5〜2.5重量部が挙げられる。 In particular, when the component (B) is a sulfobetaine type amphoteric surfactant, the content of the component (B) is 0.2 to 2.8 parts by weight, preferably 0 with respect to 1 part by weight of the component (A). 0.3 to 2.5 parts by weight, more preferably 0.4 to 2.5 parts by weight, and still more preferably 0.5 to 2.5 parts by weight.
本発明の組成物において使用される溶媒としては、薬学的に許容され、且つ上記各成分を溶解することができる限り特に限定されないが、例えば、蒸留水、イオン交換水、生理食塩水、リン酸緩衝生理食塩水、多価アルコール等が挙げられる。 The solvent used in the composition of the present invention is not particularly limited as long as it is pharmaceutically acceptable and can dissolve each of the above components. For example, distilled water, ion-exchanged water, physiological saline, phosphoric acid Examples include buffered saline and polyhydric alcohol.
また、本発明の組成物は、上記成分に加え、本発明の効果を損なわない範囲で薬学的に許容される従来公知の添加剤を含んでいてもよい。添加剤としては、例えば、防腐剤、甘味剤、香料、着色料、湿潤剤、乳化剤、可溶化剤、増粘剤、粘稠剤、発泡剤、酵素、顔料、植物抽出エキス、賦形剤、pH調整剤、等張化剤、清涼化剤、キレート剤等が挙げられるが、これらに限定されない。また、抗菌剤、抗炎症剤、麻酔剤、鎮痛剤、消臭剤、抗真菌剤、抗ウイルス剤等の薬理活性成分を含んでいてもよい。 Moreover, the composition of this invention may contain the conventionally well-known additive pharmaceutically acceptable in the range which does not impair the effect of this invention in addition to the said component. Examples of additives include preservatives, sweeteners, fragrances, colorants, wetting agents, emulsifiers, solubilizers, thickeners, thickeners, foaming agents, enzymes, pigments, plant extracts, excipients, Examples include, but are not limited to, pH adjusters, tonicity agents, cooling agents, chelating agents, and the like. Moreover, you may contain pharmacologically active components, such as an antibacterial agent, an anti-inflammatory agent, an anesthetic, an analgesic, a deodorant, an antifungal agent, and an antiviral agent.
本発明の組成物のpHは、粘膜に適用した場合に粘膜を傷害しない程度であれば特に制限されないが、例えば4〜8、好ましくは4〜6が挙げられる。本発明の組成物をこのようなpHに調整する場合は、従来公知の方法に従って行うことができ、例えば、塩酸、クエン酸、グルコン酸、コハク酸、酢酸、酒石酸、ソルビン酸、乳酸、マレイン酸、硫酸、リン酸、リンゴ酸、アルギニン、アンモニア水、ジイソプロパノールアミン、ジエタノールアミン、トリイソプロパノールアミン、トリエタノールアミン、モノエタノールアミン、水酸化カリウム、水酸化カルシウム、水酸化ナトリウム、及びこれらの塩等の緩衝剤を適宜添加して行うことができる。 The pH of the composition of the present invention is not particularly limited as long as it does not damage the mucosa when applied to the mucosa, and examples thereof include 4 to 8, preferably 4 to 6. When adjusting the composition of the present invention to such a pH, it can be performed according to a conventionally known method, for example, hydrochloric acid, citric acid, gluconic acid, succinic acid, acetic acid, tartaric acid, sorbic acid, lactic acid, maleic acid. , Sulfuric acid, phosphoric acid, malic acid, arginine, aqueous ammonia, diisopropanolamine, diethanolamine, triisopropanolamine, triethanolamine, monoethanolamine, potassium hydroxide, calcium hydroxide, sodium hydroxide, and salts thereof Buffering agents can be added as appropriate.
また、本発明の組成物の浸透圧は、生理学的に許容される範囲の浸透圧に調整されていることが望ましい。このような浸透圧としては、150〜400mOsm、好ましくは200〜400mOsm、より好ましくは200〜290mOsmである。このような範囲に浸透圧を調整することにより、更に粘膜への刺激を低減することができる。 Moreover, it is desirable that the osmotic pressure of the composition of the present invention is adjusted to an osmotic pressure within a physiologically acceptable range. Such osmotic pressure is 150 to 400 mOsm, preferably 200 to 400 mOsm, and more preferably 200 to 290 mOsm. By adjusting the osmotic pressure to such a range, the irritation to the mucous membrane can be further reduced.
以上の成分を、当該分野において通常採用される方法に従って混合することにより、本発明の組成物とすることができる。本発明の組成物の剤型は特に限定されないが、例えば、液剤、ペースト剤、軟膏剤、粉末剤、顆粒剤、錠剤、クリーム剤等の形態が挙げられる。また、本発明の組成物の用途としては、腸内洗浄剤、直腸洗浄剤、膀胱洗浄剤、膣洗浄剤、耳内洗浄剤、含嗽剤、口腔用洗浄剤、鼻腔洗浄剤等が挙げられ、好ましくは膣洗浄剤、耳内洗浄剤、含嗽剤、口腔用洗浄剤、鼻腔洗浄剤等が挙げられる。また、本発明の組成物は、前記濃度で(A)及び(B)成分を含む製品として提供されてもよく、用時に適宜水等により希釈され、(A)及び(B)成分が前記濃度範囲になるように調製された濃縮物として提供されてもよい。 The composition of the present invention can be obtained by mixing the above components according to a method usually employed in the art. Although the dosage form of the composition of this invention is not specifically limited, For example, forms, such as a liquid agent, a paste agent, an ointment, a powder agent, a granule, a tablet, a cream agent, are mentioned. Examples of the use of the composition of the present invention include intestinal cleanser, rectal cleanser, bladder cleanser, vaginal cleanser, ear cleanser, mouth rinse, oral cleanser, nasal cleanser, etc. Preferable examples include vaginal cleanser, ear cleanser, gargle, oral cleanser, nasal cleanser and the like. In addition, the composition of the present invention may be provided as a product containing the components (A) and (B) at the above concentrations, and is appropriately diluted with water or the like at the time of use, and the components (A) and (B) are contained in the above concentrations. It may be provided as a concentrate prepared to be in range.
本発明の組成物が適用される粘膜としては、特に限定されないが、例えば、鼻腔、咽頭、口腔、耳、膣、膀胱、直腸等の粘膜に対して適用することができ、好ましくは鼻腔、咽頭、口腔、耳、膣の粘膜が挙げられる。 The mucous membrane to which the composition of the present invention is applied is not particularly limited, but can be applied to mucous membranes such as nasal cavity, pharynx, oral cavity, ear, vagina, bladder, rectum, and preferably nasal cavity, pharynx , Oral, ear and vaginal mucosa.
本発明の組成物は、洗浄効果が高く、且つ粘膜への刺激が低減されていることから、粘膜の洗浄用として好適に使用される。粘膜の洗浄を目的として本発明の組成物を使用する場合の使用方法は、洗浄効果が奏される限り特に限定されないが、例えば、粘膜に滴下する方法、スプレー等で粘膜に噴霧する方法、カテーテル等により注入する方法、鼻腔であれば洗浄液を鼻腔に流しこみ、口から吐き出す方法、口腔であれば口に含んで洗口する方法及びブラシにより磨く方法等が挙げられる。また、その際の本発明の組成物の適用量は特に限定されず、適用部位の大きさ、粘膜への異物の付着の程度等を考慮して適宜設定され得るが、例えば、鼻腔粘膜の洗浄を目的とする場合であれば、10〜30mL、好ましくは15〜25mL、耳粘膜の洗浄を目的とする場合であれば、0.2〜1mL、好ましくは0.2〜0.7mL、口腔粘膜の洗浄を目的とする場合であれば、5〜30mL、好ましくは10〜20mLが例示される。 The composition of the present invention is suitably used for washing mucous membranes because of its high washing effect and reduced irritation to mucous membranes. The method of using the composition of the present invention for the purpose of washing the mucous membrane is not particularly limited as long as the cleaning effect is exerted. For example, a method of dripping onto the mucosa, a method of spraying on the mucosa by spraying, a catheter For example, there are a method of injecting by a nasal cavity, a method of pouring a cleaning solution into the nasal cavity and spitting it out of the mouth, a method of rinsing by mouth in the mouth and a method of brushing with a brush. In addition, the amount of the composition of the present invention applied at that time is not particularly limited and may be appropriately set in consideration of the size of the application site, the degree of foreign matter adhering to the mucous membrane, etc. 10 to 30 mL, preferably 15 to 25 mL, and 0.2 to 1 mL, preferably 0.2 to 0.7 mL, oral mucosa 5 to 30 mL, preferably 10 to 20 mL is exemplified for the purpose of cleaning.
以下、本発明を更に詳細に説明するが、本発明はこれらに限定されない。 Hereinafter, the present invention will be described in more detail, but the present invention is not limited thereto.
[参考試験例1]
後述する実施例及び比較例の組成物の粘膜に対する評価は、ヒト粘膜又は動物粘膜の代わりにヒト三次元培養皮膚を用いて行った。従って、予めモルモット粘膜への刺激とヒト三次元培養皮膚を用いた確認方法が相関することを確認するため、以下の予備試験を行った。
[Reference Test Example 1]
Evaluation of the compositions of Examples and Comparative Examples described later on the mucosa was performed using human three-dimensional cultured skin instead of human mucosa or animal mucosa. Therefore, the following preliminary test was conducted in order to confirm that the stimulation to the guinea pig mucosa and the confirmation method using human three-dimensional cultured skin were correlated in advance.
モルモット(雌、6週齢、30匹)を上海生旺実験動物養殖有限会社から入手した。当該モルモットの下唇直下の皮膚を引き下げ、前歯部歯肉と下唇粘膜を露出させ、当該露出した口腔粘膜部位に下表1に記載の組成物を100μL滴下投与し、30秒間、当該組成物を絵筆で塗り広げた。投与は2時間間隔で1日4回、4日間連日行った。投与終了後1日目と3日目に、前歯部歯肉及び下唇部粘膜の変化をCTFAガイドライン(Hynes,C.R, and Estrin, N. F., CTFA Safety Testing Guidelines: CTFA Technical Guidelines, Cosmetic, Toiletry and Fragarance Association, Inc., Washington,11-13(1981))に準じ、肉眼により観察した。
(細胞生存率の評価方法)
下表1に示される参考処方1〜4の組成物を培地に添加した後の、生細胞数を計測するため、MTT(3−[4,5−dimethylthiazol−2−yl]−2,5−diphenyltetrazolium bromide)アッセイを行った。評価手順は以下の通りである。
Guinea pigs (female, 6 weeks old, 30 animals) were obtained from Shanghai Ginger Experimental Animal Farming Co., Ltd. The skin just below the lower lip of the guinea pig is pulled down to expose the anterior tooth gingiva and the lower lip mucosa, and 100 μL of the composition described in Table 1 below is administered dropwise to the exposed oral mucosa, and the composition is applied for 30 seconds. Painted with a paint brush. The administration was performed 4 times a day for 4 days every 2 hours. On the 1st and 3rd day after the end of administration, changes in the anterior gingival and lower lip mucosa were detected by the CTFA Guidelines (Hynes, CR, and Estrin, NF, CTFA Safety Testing Guidelines: CTFA Technical Guidelines, Cosmetic, Toiletry and Fragarance Association). , Inc., Washington, 11-13 (1981)).
(Evaluation method of cell viability)
MTT (3- [4,5-dimethylthiazol-2-yl] -2,5- is used to measure the number of viable cells after adding the compositions of Reference Formulas 1 to 4 shown in Table 1 below to the medium. diphenyltetrazole bromide) assay was performed. The evaluation procedure is as follows.
株式会社ジャパン・ティッシュ・エンジニアリング(以下J−TEC)製ヒト三次元培養表皮(LabCyte EPI−MODEL24)を入手し、付属のアッセイ培地(0.5mL)の入った24ウェルアッセイプレートに、培養カップ(予め、カップ底面に、ヒト三次元培養表皮が接着している)を移し、37℃、5%CO2の条件に設定されたインキュベーター内で2時間培養した。下表1に示される参考処方1〜4の組成物をヒト三次元培養表皮上に25μLずつ滴下し、更に2時間培養した。培養後、ヒト三次元培養表皮の表面をPBS(−)で10回以上洗浄した後、0.5mg/mLのMTT試液(臭化3-(4,5-ジメチル-2-チアゾリル)-2,5-ジフェニル-2H-テトラゾリウム:(株)同仁化学研究所製)を用い、37℃、5%CO2の条件下で3時間インキュベートすることにより生細胞のMTT染色を行った。MTT染色の終了後、ヒト三次元培養表皮をイソプロパノール300μLに20〜25℃の暗所で16時間浸漬して細胞抽出物を得た。この細胞抽出物の570nmにおける吸光度を測定した。細胞生存率の算出を下記数式(1)に従って行った。ブランクの吸光度はイソプロパノールを用いて測定した場合の値である。
細胞生存率(%)=(細胞抽出物の吸光度−ブランクの吸光度)/
(PBS(−)の吸光度−ブランクの吸光度)×100…数式(1)
Obtain a human three-dimensional culture epidermis (LabCyte EPI-MODEL24) manufactured by Japan Tissue Engineering Co., Ltd. (hereinafter J-TEC), and place it in a 24-well assay plate containing the attached assay medium (0.5 mL). The human three-dimensional culture epidermis was previously adhered to the bottom of the cup) and cultured for 2 hours in an incubator set at 37 ° C. and 5% CO 2 . 25 μL each of the compositions of Reference Formulas 1 to 4 shown in Table 1 below was dropped on the human three-dimensional culture epidermis and further cultured for 2 hours. After culturing, the surface of the human three-dimensional cultured epidermis was washed with PBS (−) 10 times or more, and then 0.5 mg / mL MTT test solution (3- (4,5-dimethyl-2-thiazolyl bromide-2, Using 5-diphenyl-2H-tetrazolium (manufactured by Dojindo Laboratories Co., Ltd.), MTT staining of living cells was performed by incubating at 37 ° C. under 5% CO 2 for 3 hours. After completion of MTT staining, the human three-dimensional cultured epidermis was immersed in 300 μL of isopropanol in the dark at 20 to 25 ° C. for 16 hours to obtain a cell extract. The absorbance of this cell extract at 570 nm was measured. The cell viability was calculated according to the following formula (1). The absorbance of the blank is a value measured using isopropanol.
Cell viability (%) = (absorbance of cell extract−absorbance of blank) /
(Absorbance of PBS (−) − absorbance of blank) × 100 (1)
結果を下表1に示す。
表1に示される結果より、動物スコアが低い(即ち、刺激が少ない)ほど細胞生存率が高く、両者に相関性があることが示された。また、これらの結果は、ヒトにおける刺激性とも相関性があることが示された。更に、特に、(A)成分であるラウリル硫酸ナトリウムを3重量%以上含み、且つ(B)成分を含まない組成物の場合は、粘膜に対して強い刺激性を有することが示された。なお、市場では動物スコアが0〜2である口腔用組成物が許容されている。 From the results shown in Table 1, it was shown that the lower the animal score (ie, the less stimulation), the higher the cell survival rate, and the correlation between the two. These results were also shown to correlate with irritation in humans. Furthermore, in particular, the composition containing 3% by weight or more of sodium lauryl sulfate as the component (A) and not including the component (B) was shown to have strong irritation to the mucous membrane. In addition, the composition for oral cavity whose animal score is 0-2 is accept | permitted on the market.
[試験例]
下表2〜14に示される組成物をヒト三次元培養表皮に滴下する以外は、前記参考試験例1(細胞生存率の評価方法)に従い、細胞生存率について評価を行った。下表2〜14に示される組成物は、(A)成分及び(B)成分をそれぞれ水に溶解させることにより作製した。
[Test example]
The cell viability was evaluated according to Reference Test Example 1 (Method for evaluating cell viability) except that the compositions shown in Tables 2 to 14 below were dropped onto the human three-dimensional cultured epidermis. The compositions shown in Tables 2 to 14 below were prepared by dissolving the component (A) and the component (B) in water.
本試験に用いた、原料は以下のとおりである。
ラウリル硫酸ナトリウム(モノゲンY―100):第一工業製薬株式会社
ラウリルジメチルアミノ酢酸ベタイン(リカビオンA―100):新日本理化株式会社
ステアリルジメチルアミノ酢酸ベタイン(アンヒトール86B):花王株式会社
ラウリルヒドロキシスルホベタイン(アンヒトール20HD):花王株式会社
ラウリン酸アミドプロピルヒドロキシスルホベタイン(ソフタゾリンLSB):川研ファインケミカル株式会社
The raw materials used in this test are as follows.
Sodium Lauryl Sulfate (Monogen Y-100): Daiichi Kogyo Seiyaku Co., Ltd. Lauryldimethylaminoacetic acid betaine (Ricavion A-100): Shin Nippon Rika Co., Ltd. Stearyldimethylaminoacetic acid betaine (Amphithol 86B): Kao Corporation Lauryl hydroxysulfobetaine (Amphitol 20HD): Kao Corporation Lamido amidopropyl hydroxysulfobetaine (Softazoline LSB): Kawaken Fine Chemicals Co., Ltd.
(B)成分としてラウリルジメチルアミノ酢酸ベタインを使用した場合の細胞生存率を下表2〜6に示す。
(B)成分としてステアリルジメチルアミノ酢酸ベタインを使用した場合の細胞生存率を下表7及び8に示す。
表2の参考例2と比較例1とを比較すると分かるように、ラウリル硫酸ナトリウムを1重量%含有する場合に比べて、ラウリル硫酸ナトリウムの含有量が1.5重量%以上の場合の方が、細胞生存率が低く、粘膜刺激が強いことが示された。一方、実施例1から分かるように、ラウリルジメチルアミノ酢酸ベタインを、所定の含有比率で含有させることによって、ラウリル硫酸ナトリウムを1.5重量%以上含有する場合であっても、十分に細胞生存率が改善され、粘膜刺激が低減されることが示された。また、比較例2、5及び6から分かるように、ラウリル硫酸ナトリウムの含有量が3重量%以上の場合、細胞生存率は0%となり、粘膜刺激が特に強いことが示されたが、実施例2〜13と比較例2〜4とを比較すると分かるように、ラウリル硫酸ナトリウムを3重量%含有する場合であっても、ラウリルジメチルアミノ酢酸ベタインを所定の含有比率で含有させることによって、細胞生存率が顕著に上昇し、粘膜刺激が低減されることが示された。また、表5及び6から分かるように、当該刺激低減効果は、ラウリル硫酸ナトリウムを3重量%よりも多く含有する場合(例えばラウリル硫酸ナトリウムの含有量が、4重量%及び5重量%の場合)においても、同様の傾向となることが示された。また、表7及び8から分かるように、ラウリル硫酸ナトリウムに対して、ステアリルジメチルアミノ酢酸ベタインを所定の含有比率で含有する場合において、当該刺激低減効果は、ラウリルジメチルアミノ酢酸ベタインを含有させた場合と同様の傾向となることが示された。 As can be seen from a comparison between Reference Example 2 and Comparative Example 1 in Table 2, the case where the content of sodium lauryl sulfate is 1.5% by weight or more is compared to the case of containing 1% by weight of sodium lauryl sulfate. It was shown that cell viability was low and mucosal irritation was strong. On the other hand, as can be seen from Example 1, by containing lauryldimethylaminoacetic acid betaine in a predetermined content ratio, even when sodium lauryl sulfate is contained in an amount of 1.5% by weight or more, sufficient cell viability is obtained. Has been shown to improve mucosal irritation. Further, as can be seen from Comparative Examples 2, 5 and 6, when the content of sodium lauryl sulfate was 3% by weight or more, the cell viability was 0%, indicating that mucosal irritation was particularly strong. As can be seen by comparing 2 to 13 with Comparative Examples 2 to 4, even when 3% by weight of sodium lauryl sulfate is contained, cell survival can be achieved by containing lauryl dimethylaminoacetic acid betaine at a predetermined content ratio. The rate was significantly increased and mucosal irritation was shown to be reduced. Further, as can be seen from Tables 5 and 6, the irritation reduction effect is obtained when the sodium lauryl sulfate content is more than 3% by weight (for example, when the content of sodium lauryl sulfate is 4% by weight and 5% by weight). It was also shown that the same tendency was observed in. In addition, as can be seen from Tables 7 and 8, when sodium stearyldimethylaminoacetate betaine is contained in a predetermined content ratio with respect to sodium lauryl sulfate, the irritation reduction effect is obtained when lauryldimethylaminoacetate betaine is contained. It was shown that it becomes the same tendency.
(B)成分としてラウリルヒドロキシスルホベタインを使用した場合の細胞生存率を下表9〜12に示す。
(B)成分としてラウリン酸アミドプロピルヒドロキシスルホベタインを使用した場合の細胞生存率を下表13及び14に示す。
表9の実施例28〜32と比較例1、8及び9とを比較すると分かるように、ラウリル硫酸ナトリウムを1.5重量%以上含有する場合であっても、ラウリルヒドロキシスルホベタインを所定の含有比率で含有させることによって、細胞生存率が十分に改善され、粘膜刺激が低減されることが示された。また、実施例33〜45と比較例2、10及び11とを比較すると分かるように、ラウリル硫酸ナトリウムを3重量%含有する場合であっても、ラウリルヒドロキシスルホベタインを所定の含有比率で含有させることによって、細胞生存率が顕著に上昇し、粘膜刺激が低減されることが示された。 As can be seen by comparing Examples 28 to 32 in Table 9 with Comparative Examples 1, 8 and 9, even when sodium lauryl sulfate is contained in an amount of 1.5% by weight or more, lauryl hydroxysulfobetaine is contained in a predetermined amount. It was shown that the cell viability was sufficiently improved and the mucosal irritation was reduced by the inclusion in the ratio. Moreover, even if it is a case where 3 weight% of sodium lauryl sulfate is contained so that Examples 33-45 and Comparative Examples 2, 10 and 11 may be contained, lauryl hydroxysulfobetaine is contained in a predetermined content ratio. This has been shown to significantly increase cell viability and reduce mucosal irritation.
また、表11及び12から分かるように、当該刺激低減効果は、ラウリル硫酸ナトリウムを3重量%よりも多く含有する場合(例えばラウリル硫酸ナトリウムの含有量が、4重量%及び5重量%の場合)においても、同様の傾向となることが示された。また、表13及び14から分かるように、ラウリル硫酸ナトリウムに対して、ラウリン酸アミドプロピルヒドロキシスルホベタインを所定の含有比率で含有させた場合において、当該刺激低減効果は、ラウリルヒドロキシスルホベタインを含有させた場合と同様の傾向となることが示された。 Further, as can be seen from Tables 11 and 12, the irritation reduction effect is obtained when the sodium lauryl sulfate content is more than 3% by weight (for example, when the content of sodium lauryl sulfate is 4% by weight and 5% by weight). It was also shown that the same tendency was observed in. In addition, as can be seen from Tables 13 and 14, when lauric acid amidopropyl hydroxysulfobetaine is contained in a predetermined content ratio with respect to sodium lauryl sulfate, the irritation reduction effect includes lauryl hydroxysulfobetaine. It was shown that the same tendency as in the case of
以上の結果より、組成物中にアルキル硫酸エステル型界面活性剤を多量に含むことに起因する粘膜に対する刺激が、アミノ酢酸ベタイン型両性界面活性剤又はスルホベタイン型両性界面活性剤を、所定の含有比率となるように含有させることによって、顕著に低減されることが示された。特に、アルキル硫酸エステル型界面活性剤を3重量%以上含有し、且つアミノ酢酸ベタイン型両性界面活性剤又はスルホベタイン型両性界面活性剤を含有しない場合は、細胞生存率が0%となり、粘膜に強い刺激が生じることが示されたが、アミノ酢酸ベタイン型両性界面活性剤又はスルホベタイン型両性界面活性剤を含有することによって、当該刺激が低減されることが示された。 From the above results, the composition contains a predetermined amount of aminoacetic acid betaine-type amphoteric surfactant or sulfobetaine-type amphoteric surfactant due to the fact that the composition contains a large amount of alkyl sulfate ester-type surfactant. It was shown that the content was significantly reduced by the inclusion of the ratio. In particular, when the alkyl sulfate type surfactant is contained at 3% by weight or more and the aminoacetic acid betaine amphoteric surfactant or sulfobetaine type amphoteric surfactant is not contained, the cell viability becomes 0%, and the mucosa Although strong irritation was shown to occur, it was shown that the irritation was reduced by containing an aminoacetic acid betaine amphoteric surfactant or a sulfobetaine amphoteric surfactant.
また、アルキル硫酸エステル型界面活性剤の含有量が1.5重量%以上であれば、アルキル硫酸エステル型界面活性剤がどのような濃度で含有された場合であっても、アミノ酢酸ベタイン型両性界面活性剤又はスルホベタイン型両性界面活性剤を所定の含有比率となるように含有させることによる刺激低減効果は同様の傾向となることが示された。 In addition, if the content of the alkyl sulfate type surfactant is 1.5% by weight or more, the amino acetate betaine type amphotericity can be obtained regardless of the concentration of the alkyl sulfate type surfactant. It was shown that the irritation reduction effect by containing a surfactant or a sulfobetaine-type amphoteric surfactant so as to have a predetermined content ratio has a similar tendency.
[処方例]
以下の処方例に記載の組成物を従来公知の方法により原料を混合することで調製した。いずれも、実施例と同様に細胞生存率に優れ、刺激性が低い粘膜適用組成物であった。
[Prescription example]
The composition described in the following formulation examples was prepared by mixing raw materials by a conventionally known method. In any case, the composition applied to mucosa was excellent in cell viability and low in irritation as in the Examples.
Claims (7)
用時の(A)成分の含有量が1.5重量%以上、
(B)成分の含有量が(A)成分1重量部に対して0.4〜2.5重量部であり、
鼻腔、咽頭、口腔、耳、膣、膀胱及び直腸からなる群より選択される少なくとも1種の粘膜に適用される、粘膜適用組成物(但し、デキストラナーゼを含有する場合を除く)。 (A) alkyl sulfate ester type surfactant and (B) aminoacetic acid betaine type amphoteric surfactant ,
The content of the component (A) at the time of use is 1.5% by weight or more,
The content of the component (B) is 0.4 to 2.5 parts by weight with respect to 1 part by weight of the component (A),
Mucosal composition applied to at least one mucosa selected from the group consisting of nasal cavity, pharynx, oral cavity, ear, vagina, bladder and rectum (except when it contains dextranase).
用時の(A)成分の含有量が1.5重量%以上、 The content of the component (A) at the time of use is 1.5% by weight or more,
(B)成分の含有量が(A)成分1重量部に対して0.2〜2.8重量部であり、 The content of the component (B) is 0.2 to 2.8 parts by weight with respect to 1 part by weight of the component (A),
鼻腔、咽頭、口腔、耳、膣、膀胱及び直腸からなる群より選択される少なくとも1種の粘膜に適用される、粘膜適用組成物(但し、デキストラナーゼを含有する場合を除く)。 Mucosal composition applied to at least one mucosa selected from the group consisting of nasal cavity, pharynx, oral cavity, ear, vagina, bladder and rectum (except when it contains dextranase).
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012081822A JP6047295B2 (en) | 2012-03-30 | 2012-03-30 | Mucosal composition |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2012081822A JP6047295B2 (en) | 2012-03-30 | 2012-03-30 | Mucosal composition |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013209336A JP2013209336A (en) | 2013-10-10 |
JP6047295B2 true JP6047295B2 (en) | 2016-12-21 |
Family
ID=49527560
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012081822A Active JP6047295B2 (en) | 2012-03-30 | 2012-03-30 | Mucosal composition |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP6047295B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6688072B2 (en) * | 2015-12-28 | 2020-04-28 | 花王株式会社 | Liquid oral composition |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS60197614A (en) * | 1984-03-21 | 1985-10-07 | Shionogi & Co Ltd | Shampoo composition of low irritation |
ZA853905B (en) * | 1984-06-12 | 1986-12-30 | Colgate Palmolive Co | Stable dentifrice containing dextranase |
JPS61188496A (en) * | 1985-02-14 | 1986-08-22 | フジックス株式会社 | Detergent composition |
GB9201519D0 (en) * | 1992-01-24 | 1992-03-11 | Unilever Plc | Detergent compositions |
JPH06287114A (en) * | 1993-03-31 | 1994-10-11 | Sunstar Inc | Shampoo composition |
JPH11505840A (en) * | 1995-05-27 | 1999-05-25 | ザ、プロクター、エンド、ギャンブル、カンパニー | Cleansing composition |
JPH09110892A (en) * | 1995-10-20 | 1997-04-28 | Shiseido Co Ltd | Trehalose hydroxyaliphatic ether |
JPH1149654A (en) * | 1997-07-31 | 1999-02-23 | Lion Corp | Oral composition |
FR2792195B1 (en) * | 1999-04-19 | 2003-02-21 | Ceca Sa | METHOD FOR FORMULATING A NON-IRRITATING AND NON-TOXIC ANTIFUNGAL AGENT IN SURFACTANT AND AQUEOUS COMPOSITIONS FOR CLEANING THE SKIN |
FR2865401B1 (en) * | 2004-01-27 | 2006-04-28 | Oreal | COMPOSITION FOR CLEANING THE SKIN |
-
2012
- 2012-03-30 JP JP2012081822A patent/JP6047295B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2013209336A (en) | 2013-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9848600B2 (en) | Biofilm disruptive compositions | |
TW467749B (en) | Mouthwash compositions comprising CPC | |
US9107856B2 (en) | Dental appliance cleanser | |
JP2018535933A (en) | Personal cleansing composition and method for stabilizing a microbiome | |
TW201404408A (en) | Liquid cleansing agent in non-gas foaming container | |
CN103354741B (en) | Oral care composition | |
CN104586653A (en) | Hair and body wash suitable for infants and preparation method for hair and body wash | |
JP2008303188A (en) | Candida biofilm eliminating agent | |
JPH03130300A (en) | High-molecular condensation product of protein/fatty acid having very good allowability by skin or mucous membrane | |
KR20140093881A (en) | Composition of foaming tablet | |
JP5959271B2 (en) | Mucosal composition | |
JP6047295B2 (en) | Mucosal composition | |
JP2007031376A (en) | Hair and scalp detergent, percutaneous absorption accelerator and percutaneous absorption accelerating method | |
JP2011098961A (en) | Ophthalmic composition for nonionic silicone hydrogel contact lens | |
RU2638799C2 (en) | Zinc coceth sulphate application in capacity of antibacterial agent for propionibacterium acnes | |
JP2006347914A (en) | Skin cleaner composition | |
JP2003226636A (en) | Weak-acidic cleansing preparation | |
JP3920129B2 (en) | Cleaning composition | |
JP3442565B2 (en) | Detergent composition | |
JPH0774141B2 (en) | Denture cleanser | |
US20120237901A1 (en) | Denture Adhesive Remover for Intraoral and Extraoral Use | |
JPH05262631A (en) | Oral cavity composition for denture-wearing person | |
JP2022007545A (en) | Composition for mucosal cleaning | |
JP6425400B2 (en) | Composition used in contact with skin surface | |
JP2022007543A (en) | Composition for mucosal cleaning |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150226 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20151112 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151124 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160122 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160607 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160805 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161004 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20161025 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20161121 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6047295 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |